A trial to investigate the efficacy and safety of SER-109 in patients with recurrent Clostridium difficile infections
Phase of Trial: Phase I/II
Latest Information Update: 25 Feb 2016
At a glance
- Drugs SER 109 (Primary)
- Indications Clostridium infections
- Focus Therapeutic Use
- Sponsors Seres Health
- 25 Feb 2016 According to Seres Therapeutics media release, the FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations.
- 09 Feb 2016 According to a Seres Therapeutics media release, results from this study were published in The Journal of Infectious Diseases.
- 09 Feb 2016 Results were published in a Seres Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History